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AT-1 receptor blockade prevents proteinuria, renal failure, hy-
perlipidemia, and glomerulosclerosis in the Imai rat.
Background. The Imai rat is a model of spontaneous fo-
cal glomerulosclerosis which leads to nephrotic syndrome, hy-
perlipidemia, hypertension, and progressive renal failure. We
evaluated the effects of angiotensin II receptor type 1 (AT-1)
blockade, and compared the results with the effects of the ad-
ministration of hypolipidemic treatment with a 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
All treatments were started at 10 weeks of age when the rats
were already proteinuric and continued for 6 months when rats
were sacrificed.
Methods. The following groups (N = 6 each) were studied: (1)
control Sprague-Dawley rats, 34 weeks old; (2) Imai group that
received vehicle; (3) Imai + angiotensin II receptor blockade
(ARB) group that received olmesartan (10 mg/kg/day by gas-
tric gavage); (4) Imai + prava group, that received pravastatin
(20 mg/kg/day by gastric gavage); and (5) Imai + ARB + prava
group that received both ARB and pravastatin. Lipid profile,
renal function, and structure were assessed at 6 months.
Results. As expected, the untreated Imai rats exhib-
ited heavy proteinuria, hypoalbuminemia, hypertension, re-
nal insufficiency, marked glomerulosclerosis, tubulointerstitial
inflammation, and profound hyperlipidemia. Pravastatin treat-
ment alone led to a significant, but partial improvement of hy-
perlipidemia and renal disease. The ARB treatment alone or
in combination with pravastatin resulted in normalization of
the blood pressure, urinary protein excretion, plasma choles-
terol, triglycerides, low-density lipoproteins (LDLs), very low-
density lipoproteins (VLDLs), and albumin concentrations and
renal function. Significant glomerulosclerosis was prevented
and tubulointerstitial injury and immune cell infiltration were
reduced by long-term AT-1 blockade.
Conclusion. The study revealed that long-term AT-1 block-
ade corrects proteinuria, hyperlipidemia, and nephropathy in
this model of spontaneous glomerulosclerosis.
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The Imai rat is a murine strain derived from Sprague-
Dawley rat that was originally developed as an animal
model of spontaneous hyperlipidemia. Subsequent stud-
ies revealed that male Imai rats presented with protein-
uria and hyperlipidemia starting at 6 to 8 weeks of age
and developed impaired renal function after 8 to 9 months
with renal histologic changes of focal segmental glomeru-
losclerosis (FSGS) [1]. Female Imai rats have less severe
disease which is worsened by ovariectomy [2]. Several in-
vestigations have shown beneficial effects of dietary pro-
tein restriction and oral adsorbent AST-120 [3], gonadal
hormone modifications, [4], somatostatin analogues [5],
alcohol extracts of soy protein [6], and antihypertensive
therapy [7], but the potential usefulness of angiotensin
II receptor blockers (ARBs) has not been explored.
Yet, it appeared likely that a major benefit could be
achieved with these drugs since the administration of the
angiotensin-converting enzyme (ACE) blocker enalapril
reduced both proteinuria and hypercholesterolemia [8].
Furthermore, treatment with angiotensin receptor antag-
onists has proven beneficial in some patients with FSGS
resistant to immunosuppressive treatment [8] and ACE
inhibitors may have a direct hypolipidemic effect, in ad-
dition to the indirect effect resulting from the reduction
of proteinuria, in patients with chronic nephropathies [9].
Therefore, we evaluated the use of angiotensin II re-
ceptor type 1 (AT-1) blockade on the nephropathy of the
Imai rat and compared the results with the lipid-lowering
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitor, pravastatin, and a combination of
both therapies.
METHODS
Male Imai rats and male Sprague-Dawley control rats
were obtained from Biological Research Laboratories
(Takeda Clinical Industries, Osaka, Japan). The animals
were provided free access to regular rat chow and water.
The study protocols were approved by the Animal Care
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and Ethical Committee of the Saga Medical School, Saga,
Japan.
Baseline studies were done in 8-week-old rats: (1)
Sprague-Dawley 8-week-old group (N = 6) and (2) Imai
8-week-old group (N = 6).
Experimental groups consisted of rats given a specific
treatment (see below) for a period of 6 months, starting
at 10 weeks of age and continued up to 34 weeks of age,
when all animals were euthanized. The following groups
were studied: (1) control Sprague-Dawley group (N =
6), 34 weeks old; (2) control Imai group (N = 6) that re-
ceived vehicle; (3) ARB group (Imai + ARB) (N = 6)
that received the AT-1 receptor blocker olmesartan
(Sankyo Pharmaceutical Co., Tokyo, Japan) at a dose
of 10 mg/kg/day by gastric gavage; (4) HMG-Co A re-
ductase inhibitor group (Imai + prava) (N = 6) that re-
ceived pravastatin (Bristol Myer Squibb Co., Princeton,
NJ, USA) at a dose of 20 mg/kg/day by gastric gavage;
and (5) combined therapy group (Imai + ARB + prava)
(N = 6) that received both olmesartan and pravastatin in
similar doses and by a similar route of administration as
the ARB group and pravastatin groups described above,
during the 6 months of treatment.
Systolic blood pressure was determined by tail cuff
plethysmography as detailed in previous communications
[10]. Rats were sacrificed under barbital anesthesia at
the end of the experiment, and kidneys were harvested,
weighed, and processed for light microscopy and im-
munohistology as described in previous communications
[11].
Plasma creatinine, urea nitrogen, cholesterol, albu-
min, and triglycerides were measured by Synchro CX3
autoanalyzer (Beckman Instruments, Fullerton, CA,
USA). Urine protein was quantified by a kit purchased
from Wako Pure Chemical Industries (Tokyo, Japan).
Low-density lipoproteins (LDLs) and very low-density
lipoproteins (VLDLs) were determined by ultracen-
trifugation as previously described [12]. Proteinuria was
determined in 24-hour urine collections and creatinine
clearance was calculated and expressed in absolute val-
ues and as mL/min/g kidney weight.
Light microscopy was used to study renal histology us-
ing hematoxylin and eosin and periodic acid-Schiff (PAS)
stainings. Glomerular sclerosis was evaluated in a mini-
mum of 40 glomeruli (range 40 to 106) per biopsy using
a score described by Raij, Azar and Keane [13]. In this
score, the individual glomerulus is graded from 0 (nor-
mal) to +4 (>75% sclerosis) and the final glomerular
sclerosis index of each biopsy is calculated from these
values in percent values so that the score range extends
from 0 (normal) to 400 (all glomeruli present a 4+ scle-
rosis), as described in detail in a previous communication
[14]. Tubulointerstitial injury was evaluated in the entire
cortical and subcortical areas in each biopsy section using
a previously described score that ranged from 0 (normal)
Table 1. Renal function, lipid profile and blood pressure of young
(8 weeks) Imai and Sprague-Dawley rats
Sprague-
Dawley Imai
Cholesterol mg/dL 63.7 ± 2.9 74.0 ± 2.5a
Low-density lipoprotein mg/dL 12.3 ± 3.0 14.6 ± 3.5
Very low-density lipoprotein mg/dL 23.4 ± 1.5 29.6 ± 5.1
Triglycerides mg/dL 73.1 ± 10.2 107.2 ± 14.4b
Very low-density lipoprotein mg/dL 63.0 ± 10.2 98.9 ± 9.2a
Albumin g/dL 3.7 ± 0.1 3.5 ± 0.1
Creatinine mg/dL 0.54 ± 0.29 0.43 ± 0.01
Creatine clearance mL/min/g 0.54 ± 0.03 0.49 ± 0.03
kidney weight
Proteinuria mg/24 hours 15.2 ± 5.5 103.0 ± 13.6c
Systolic blood pressure mm Hg 116.7 ± 5.9 133.6 ± 8.6
Data are mean ± SEM. aP < 0.05; bP = 0.069; cP < 0.001.
to 5+ (>75% of the tubulointerstitial areas in cortical and
juxtamedullary regions presented infiltration, tubular di-
latation or fibrosis) [14, 15].
Indirect immunohistology was used to evaluate in-
filtration of lymphocytes (CD5 positive cells) and
macrophages (ED1-positive cells) ion the kidney by im-
munoperoxidase methodology as reported in previous in-
vestigations [11, 16–18]. Cellular counts in the glomeruli
were expressed as positive cells per glomerular cross
section (gcs) and in tubulointerstitial areas as positive
cells/mm2.
Monoclonal antibodies were used to identify lympho-
cytes (anti-CD5 clone MRCOX19) (Biosource, Camar-
illo, CA, USA) and macrophages (anti-ED1) (Harlan
Bioproducts, Indianapolis, IN, USA). Secondary rat an-
timouse and donkey antirabbit antibodies with minimal
cross reactivity to rat serum proteins were obtained from
Accurate Chemical and Scientific Co. (Westbury, NY,
USA).
A commercially available statistical package (Instat)
(GraphPadR, San Diego, CA, USA) was used to evalu-
ate the probability of the differences observed between
groups [analysis of variance (ANOVA) and Tukey post
hoc tests] and to determine the correlations between vari-
ables (Pearson’s correlation coefficient). P values <0.05
(two-tailed) were considered significant.
RESULTS
Table 1 shows the renal function, lipid profile and blood
pressure of the 8-week old Imai rats in comparison with
the control Spague-Dawley rats. Urine protein excretion,
total cholesterol and VLDL triglycerides were signifi-
cantly elevated in the 8-week-old Imai group. Systolic
blood pressure was higher in the 8-week-old Imai group
than the 8-week-old Sprague-Dawley group but the dif-
ference did not reach statistical significance.
Table 2 shows body and kidney weights, renal func-
tion, plasma albumin, proteinuria, and blood pressure at
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Table 2. Body and kidney weight, renal function, albumin, proteinuria, and systolic blood pressure in the experimental groups at 34 weeks of age
after 6 months of treatment
Sprague-Dawley Imai Imai + ARB Imai + prava Imai + ARB +
control (N = 6) (N = 6) (N = 6) (N = 6) prava (N = 6)
Body weight g 676 ± 72.3a 503.2 ± 55.6 543 ± 7.34 509 ± 5.3 511 ± 8.00
Kidney weight g 3.46 ± 0.20b 6.65 ± 0.92 3.82 ± 0.17b 4.56 ± 0.61b 3.46 ± 0.22b
Creatinine mg/dL 0.32 ± 0.03c 1.44 ± 0.89 0.27 ± 0.07c 0.69 ± 0.45 0.30 ± 0.10c
Creatine clearance mL/min 6.34 ± 1.76b 1.07 ± 0.71 5.52 ± 2.24b 2.15 ± 0.84d 4.61 ± 1.83c
Blood urea nitrogen mg/dL 17 ± 3b 85 ± 36 15 ± 2b 25 ± 14b 12 ± 1b
Albumin g/dL 3.6 ± 0.1b 2.6 ± 0.2 3.8 ± 0.2b 2.9 ± 0.3e 3.3 ± 0.6c
Proteinuria mg/24 hours 15.6 ± 4.91b 498.8 ± 195.3 16.7 ± 4.87b 330.2 ± 89.2e 14.3 ± 16.3b
Systolic blood pressure mm Hg 98.2 ± 13.8b 175.9 ± 12.3 98.8 ± 8.07b 146.2 ± 6.48b,e 110.2 ± 12.71b
Values are mean ± SD.
aP < 0.001 vs. the rest; bP < 0.001; cP < 0.001 vs. Imai; dP < 0.01; eP < 0.001 vs. ARB and ARB + prava.
34 weeks of age in Sprague-Dawley and Imai rats, un-
treated and treated for 6 months with the corresponding
therapies. Body weights of all the Imai rat groups were
comparable among themselves and lower than those of
the Sprague-Dawley rats of similar age. In contrast, the
kidney weight of the untreated Imai group was signif-
icantly higher than those of the age-matched Sprague-
Dawley group and Imai rats that were treated with ARB,
pravastatin, or both. (Table 2).
Plasma creatinine, blood urea nitrogen, urine protein
excretion and blood pressure were significantly elevated
while creatinine clearance and plasma albumin were sig-
nificantly depressed in the untreated Imai rats. These
abnormalities were prevented with long-term treatment
with ARB alone or in combination with pravastatin
(Table 2). The treatment with pravastatin alone
significantly improved but did not completely prevent
proteinuria, renal insufficiency, hypertension or hyper-
lipidemia. Acccordingly, HMG-CoA reductase inhibition
was less effective than AT-1 blockade in preventing pro-
gression of renal disease, proteinuria, and hypertension
in this model (Table 2).
The effects of drug treatment on the lipid profile in the
Imai rats are shown in Figures 1 through 4. The results
demonstrate that the changes induced in the lipid profile
by the treatments parallel the changes observed in renal
function. ARB administration alone or in combination
with pravastatin resulted in normalization of the choles-
terol (Fig. 1), triglycerides (Fig. 2), LDL (Fig. 3), and
VLDL (Fig. 4). As expected, administration of pravas-
tatin alone resulted in a significant reduction of blood
lipids as well. However, the effect observed with pravas-
tatin alone was less pronounced than the ARB (P < 0.01)
(Figs. 1 to 4). Essentially similar findings were observed
with the plasma chylomicron concentration that was in-
creased 4.7 times in the untreated Imai rats and normal-
ized in the ARB-treated rats and partially improved in
the statin-treated group (Sprague-Dawley = 64.8 ± 12.7
mg/dL; Imai = 309 ± 42 mg/dL; Imai + ARB = 81.6 ±
25 mg/dL; and Imai + prava = 217.8 ± 184.2 mg/dL).
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Fig. 1. Plasma cholesterol concentration in experimental groups and
in control Sprague-Dawley (SD) rats. Experimental groups, consist of
Imai rats, untreated (Imai) and treated with olesartan (IMAI + ARB),
with pravastatin (IMAI + PRAVA), and with both treatments (IMAI
+ ARB + PRAVA). Control Sprague-Dawley rats and experimental
groups are age-matched (34 weeks of age). ∗∗∗P < 0.001, ∗∗P < 0.01.
There were significant direct correlations between pro-
teinuria and plasma triglyceride (r = 0.721, P < 0.001) and
cholesterol (r = 0.818, P < 0.001) concentrations and a
negative correlation between plasma albumin and triglyc-
eride (r = −0.687, P < 0.001) and cholesterol concentra-
tions (r = −0.738, P < 0.001).
Histologic changes and cellular infiltration data are
shown in Table 3 and Figure 5. Glomerulosclerosis and
tubulointerstitial damage were very intense in the un-
treated Imai rats. Widespread tubular dilatation, numer-
ous protein casts, interstitial inflammatory infiltration and
areas of fibrosis coexisted with glomerulosclerosis that
frequently occupied the majority of the glomerular tuft
(Fig. 5A and B). Glomerulosclerosis index and tubuloin-
terstitial damage score were impressively reduced by the
administration of ARB, alone and in combination with
pravastatin (Table 3) (Fig. 5C and D).
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Fig. 2. Plasma triglyceride concentration in experimental groups and
in control Sprague-Dawley (SD) rats. Experimental groups, consist of
Imai rats, untreated (Imai) and treated with olesartan (IMAI + ARB),
with pravastatin (IMAI + PRAVA), and with both treatments (IMAI
+ ARB + PRAVA). Control Sprague-Dawley rats and experimental
groups are age-matched (34 weeks of age). ∗∗∗P < 0.001.
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Fig. 3. Low-density lipoprotein (LDL) concentration in experimental
groups and in control Sprague-Dawley (SD) rats. Experimental groups,
consist of Imai rats, untreated (Imai) and treated with olesartan (IMAI
+ ARB), with pravastatin (IMAI + PRAVA), and with both treatments
(IMAI + ARB + PRAVA). Control Sprague-Dawley rats and experi-
mental groups are age-matched (34 weeks of age). ∗∗∗P < 0.001, ∗∗P <
0.01.
Immune cell infiltration was scarce in the glomeruli
and not significantly different among the experimen-
tal groups. In contrast, tubulointerstitial areas in the
untreated Imai rats showed lymphocyte (CD5-positive
cells) and macrophage (ED1-positive cells) infiltration
that amounted to four to five times the values observed
in the Sprague-Dawley rats (Table 3). All treatment reg-
imens reduced significantly the tubulointerstitial infiltra-
tion of CD5-positive cells but only the treatment with
AT-1 blocker alone or in combination with pravastatin
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Fig. 4. Very low-density lipoprotein (VLDL) concentration in experi-
mental groups and in control Sprague-Dawley (SD) rats. Experimental
groups, consist of Imai rats, untreated (Imai) and treated with olesartan
(IMAI + ARB), with pravastatin (IMAI + PRAVA), and with both
treatments (IMAI + ARB + PRAVA). Control Sprague-Dawley rats
and experimental groups are age-matched (34 weeks of age). ∗∗∗P <
0.001, ∗∗P < 0.01.
reduced significantly the infiltration of ED1-positive cells
(Table 3).
There were significant positive correlations between
the proteinuria in the various groups of Imai rats and
the tubulointerstitial cell infiltration of lymphocytes (r =
0.665, P < 0.001) and, particularly, with the infiltration
of macrophages (r = 0.704, P < 0.0001). The latter rela-
tionship is shown in Figure 6. The intensity of the tubu-
lointerstitial mononuclear cell infiltration correlated with
the blood pressure levels. The correlation was stronger
for the macrophage infiltration (r = 0.736, P < 0.0001)
(Fig. 7) than for the lymphocyte infiltration (r = 0.624,
P = 0.0011).
DISCUSSION
The central findings of this investigation are that the
long-term administration of an AT-1 blocker alone or in
combination with a statin reversed the proteinuria, cor-
rected the hyperlipidemia, and prevented renal failure in
the Imai rat. ARB administration was started at 10 weeks
of age, at which point, the Imai rats already had mild but
significant proteinuria, hypercholesterolemia, and hyper-
triglyceridemia (P = 0.069), pointing to the presence of
the metabolic and renal disease at this time.
These results indicate that angiotensin hyperactivity
may play a central role in the progressive nephropa-
thy of the Imai rats. This supposition is supported
by the findings of Sakemi and Baba [7] who demonstrated
that ACE inhibition reduced proteinuria, hypercholes-
terolemia, and glomerular damage independently of its
blood pressure lowering effects, since other medications
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Table 3. Histologic findings and cellular infiltration
Sprague-Dawley Imai Imai + ARB Imai + prava Imai + ARB +
control (N = 6) (N = 6) (N = 6) (N = 6) prava (N = 6)
Glomerular sclerosis index 2.28 ± 1.20a 261.3 ± 54.4 4.04 ± 1.38a 110.1 ± 44.8b 4.70 ± 1.49a
TI damage score 0.33 ± 0.51a 4.66 ± 0.51 1.00 ± 0.89a 2.50 ± 0.54b 0.66 ± 0.51a
CD5 + cells in
Glomeruli/gcs 0.25 ± 0.27 0.42 ± 0.38 0.12 ± 0.20 0.16 ± 0.14 0.34 ± 0.39
TI/mm2 8.16 ± 1.72b 43.7 ± 3.75 32.3 ± 4.47c 31.1 ± 8.32c 25.6 ± 3.11a
ED1 + cells in
Glomeruli/gcs 0.17 ± 0.26 0.33 ± 0.41 0.17 ± 0.26 0.14 ± 0.19 0.15 ± 0.20
TI/mm2 5.36 ± 2.40b 22.03 ± 2.40 17.2 ± 2.21c 19.7 ± 2.67 16.1 ± 4.66a
aP < 0.001 vs. Imai; bP < 0.001 vs. the rest; cP < 0.01.
with similar antihypertensive activity failed to modify the
renal disease. Our results complement these findings and,
in addition, demonstrate that normalization of the pro-
teinuria and hyperlipidemia are associated with an almost
complete preservation of renal structure. This is based on
histologic findings which were essentially normal in the
Imai rats treated with ARB alone or in combination with
pravastatin.
Treatment with HMG-CoA reductase inhibitor alone
resulted in a significant but partial improvement of
plasma lipids (Figs. 1 to 4), renal function, proteinuria
(Table 1) and glomerulosclerosis (Table 3) (Fig. 5). LDL
and other atherogenic lipoproteins are known to trig-
ger intracellular signaling pathways involved in mesan-
gial cell proliferation and matrix production (reviewed
in [19]), events that are central to the pathogenesis of
glomerulosclerosis. Thus, partial improvement of renal
function and structure observed in the statin-treated
Imai rats could be, in part, related to the attenuation
of hyperlipidemia. In addition, statins may favorably af-
fect the course of renal disease via lipid-independent
mechanisms.
It is of note that administration of HMG-CoA reduc-
tase alone significantly improved, but did not normalize,
plasma lipid profile in the Imai rats. These observations
illustrate that without correction of the underlying re-
nal disease and proteinuria the normalization of the lipid
profile in the nephrotic syndrome is, at best, difficult to
achieve. This is because both increased lipid production
capacity [20, 22] and more important, impaired clear-
ance of cholesterol-rich and triglyceride-rich lipopro-
teins [20] are involved in the pathogenesis of nephrotic
hyperlipidemia [23]. The latter is occasioned by ac-
quired deficiencies of lecithin:cholesterol acytransferase
(LCAT) [12, 24], LDL receptor [25], HDL receptor [26],
lipoprotein lipase [27], VLDL receptor [28], and hepatic
triglyceride lipase [29], which are primarily caused by pro-
teinuria [23]. For these reasons, inhibition of lipid biosyn-
thesis alone may not fully normalize lipid metabolism
and plasma lipid profile in the face of persistent underly-
ing renal disease and the above mentioned deficiencies.
These observations account for the partial ameliora-
tion, but not complete correction, of hyperlipidemia
with HMG-CoA reductase inhibition in the Imai rats.
This contrasts the dramatic improvement of plasma lipid
profile which was associated with and primarily due to
prevention of proteinuria and renal insufficiency in the
ARB-treated Imai rats. Accordingly, reversal of hyper-
lipidemia by AT-1 blockade which effectively improved
the kidney disease, points to the central contribution of
the nephropathy to the pathogenesis of hyperlipidemia
in the Imai rats. The dosage of pravastatin employed in
this study (20 mg/kg/day) was based on the amount com-
monly used in the rats [31–33], a much higher dose than
the dose used to treat hypercholesterolemia in humans
(about 20 mg/day), which reflects major differences in
drug metabolism between to the two species.
The beneficial effects of ARB in early, but estab-
lished, phase of glomerulosclerosis have been shown in
the 5/6 nephrectomy rats where the combination of these
drugs with mycophenolate mofetil, but not mycopheno-
tate mofetil alone, can arrest progression and improve
established renal damage [34, 35]. Similar beneficial ef-
fects over established glomerulosclerosis were observed
by Reddi et al [36] in type 2 diabetic rats treated for
16 weeks with an ACE inhibitor.
Even though direct effects of the AT-1 blocker on in-
trinsic mechanisms resulting in glomerulosclerosis can
not be ruled out, there are several angiotensin-mediated
pathogenic mechanisms that can be potentially inter-
rupted by the ARB therapy in the Imai rat. Among
them are (1) prevention of atherosclerosis, an effect that
appears independent of changes in blood pressure or
plasma cholesterol (reviewed in [37]), (2) possible reduc-
tion in oxidative stress and preservation of endothelium-
dependent vasodilatation [38], (3) improvement in the
intraglomerular hemodynamic abnormalities resulting
from a progressive reduction of nephron units [39], (4)
correction (normalization) of systemic hypertension, (5)
blockade of angiotensin-dependent intrarenal inflamma-
tion induced by proteinuria [40, 41], and (6) reduction
of mesangial matrix accumulation. Thus, blockade of an-
giotensin system can ameliorate proteinuria and retard
progression of renal disease by a variety of biochemical
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Fig. 5. Light microscopy microphotographs of a renal biopsy of an un-
treated Imai rat. (A) Widespread tubular dilatation with widening of
the interstitial areas with intense infiltration. (B) The arrow in (A) indi-
cates the glomerulus shown in higher magnification, showing glomeru-
lar sclerosis in about 70% of the glomerular tuft. (B and C) correspond
to findings in the renal biopsy of an Imai rat treated with pravastatin
for 6 months (from week 10 to week 34). Significant tubular dilata-
tion is evident in about 30% to 40% of the tubulointerstitial area and
glomerulosclerosis in about 50% of the glomerulus shown in (D), which
corresponds to the glomerulus marked with an arrow in (C). (E and F)
correspond to the biopsy of an Imai rat treated with olesartan for 6
months. Essentially normal architecture is seen in tubulointerstitial ar-
eas and in glomeruli are shown in Figure 7C, which corresponds to the
glomerulus indicated by an arrow in (E) [all stainings are with periodic
acid-Schiff (PAS), lower magnifications × 100, higher magnifications
×400]. Interstitial infiltration of lymphocytes (CD5-positive cells) in an
Imai rat (untreated), shown in (G), is reduced by olesartan treatment
(H) (immunoperoxidase staining, original magnification ×400).
and hemodynamic mechanisms. In this regard, a direct
relationship between the intensity of proteinuria and the
infiltration of immunocompetent cells in tubulointersti-
tium (Fig. 6) has been reported in previous investigations
[42]. Therefore, it is not surprising that the reduction of
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Fig. 6. Correlation between the intensity of the macrophage infiltra-
tion and the severity of the proteinuria. Experimental groups, consist of
Imai rats, untreated (Imai) and treated with olesartan (IMAI + ARB),
with pravastatin (IMAI + PRAVA), and with both treatments (IMAI
+ ARB + PRAVA). Control Sprague-Dawley rats and experimental
groups are age-matched (34 weeks of age) (r = 0.704, P < 0.0001). Bar
represents the data in control 34-week old Sprague-Dawley rats.
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Fig. 7. Correlation between the intensity of macrophage infiltration
(ED1-positive cells) in tubulointerstitial area and systolic blood pres-
sure. Experimental groups, consist of Imai rats, untreated (Imai) and
treated with olesartan (IMAI + ARB), with pravastatin (IMAI +
PRAVA), and with both treatments (IMAI + ARB + PRAVA). Con-
trol Sprague-Dawley rats and experimental groups are age-matched
(34 weeks of age) (r = 0.736, P < 0.0001).
proteinuria was associated with a reduction in the inter-
stitial infiltration of lymphocytes and macrophages in the
treated Imai rats (Table 3). The anti-inflammatory effect
obtained with blockade of angiotensin action and the re-
duction in proteinuria is likely to have played a major role
in the preservation of renal function and structure in the
Imai rats. In fact, the proteinuria-induced inflammation
is considered to play a major part in the progression of
renal injury to end-stage renal failure [43].
The immune cell infiltration may also play a role in
the pathogenesis of sodium retention and the develop-
ment of hypertension in the nephrotic syndrome [44].
The prohypertensive characteristics of the interstitial cell
infiltration and its relationship with oxidative stress and
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intrarenal angiotensin II activity have been recently re-
viewed [45].
The correlation between the intensity of the interstitial
inflammatory reaction and the severity of hypertension
shown in this study (Fig. 9) is in agreement with previous
observations [11, 46].
In addition to the beneficial effects mentioned above,
ARB may have lipid-lowering effects that could con-
tribute to the correction of the hyperlipidemia of the
Imai rat. The improvement in proteinuria and hypoal-
buminemia is expected to reduce hyperlipidemia since
those conditions contribute independently to the impair-
ment in lipoprotein catabolism in the nephrotic syndrome
[47]. In addition, ARB may have a direct lowering effect
on plasma triglyceride concentration [10], which could
contribute to the overall effect of this medication in the
Imai rat.
CONCLUSION
The long-term administration of ARB alone or in com-
bination with a statin prevents proteinuria, hyperlipi-
demia, and renal failure in the Imai rat with spontaneous
glomerulosclerosis. The present study offers additional
evidence for the beneficial effect of AT-1 blockade in pro-
teinuric nephropathies.
Reprint requests to Bernardo Rodrı´guez-Iturbe, Renal Service, Hos-
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